Trials / Conditions / Marginal Zone Lymphoma (MZL)

Marginal Zone Lymphoma (MZL)

26 registered clinical trials studyying Marginal Zone Lymphoma (MZL) — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946	LTZ Therapeutics, Inc.	Phase 1
Not Yet Recruiting	Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma NCT07299331	Zhengzhou University	N/A
Recruiting	Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Ly NCT07355699	Beijing Tongren Hospital	Phase 4
Recruiting	Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. NCT07372365	The First Affiliated Hospital of Soochow University	Phase 2
Enrolling By Invitation	Watch and Wait or Worry and Wait in Indolent Lymphoma NCT07173790	Seoul National University Hospital	—
Active Not Recruiting	Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL NCT07480863	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Active Not Recruiting	Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma NCT07247383	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Recruiting	Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL NCT07208981	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Recruiting	Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL NCT07448324	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Recruiting	Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma NCT07022223	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Recruiting	MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL NCT06793189	Ruijin Hospital	Phase 2
Recruiting	Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in I NCT06823960	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Recruiting	Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial NCT06700798	Fei Li	Phase 2
Recruiting	Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011	iOMEDICO AG	—
Terminated	A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052	MingSight Pharmaceuticals, Inc	Phase 1 / Phase 2
Withdrawn	To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphom NCT04796922	Incyte Corporation	Phase 3
Recruiting	A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022	Nurix Therapeutics, Inc.	Phase 1
Completed	Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Recruiting	A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137	Nurix Therapeutics, Inc.	Phase 1
Completed	Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354	Calibr, a division of Scripps Research	Phase 1
Completed	CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069	Calibr, a division of Scripps Research	Phase 1
Unknown	Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZ NCT04431089	Nanjing Sanhome Pharmaceutical, Co., Ltd.	Phase 2
Recruiting	REal World Data in LYmphoma and Survival in Adults NCT03869619	Hospices Civils de Lyon	—
Active Not Recruiting	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037	Genmab	Phase 1 / Phase 2
Terminated	A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115	MEI Pharma, Inc.	Phase 1
Unknown	Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 NCT03265158	Royal Marsden NHS Foundation Trust	—